IL1B and Alzheimer disease: Different therapeutic strategies of AD target the neuroinflammation, including the inhibition of the gene expression of the cytokines and blocking their receptors, counteracting IL1-β and TNF-α effects by using antibodies that also bind their receptors and lowering the anti-inflammatory molecules Aβ and tau pathologies by limiting glial cell release of pro-inflammatory cytokines such as minocycline [111].